New Risk • May 02
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Market cap is less than US$10m (€7.74m market cap, or US$9.07m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). New Risk • Apr 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.62m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.5m). Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €7.68, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 39% over the past three years. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €7.04, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 42% over the past three years. New Risk • Mar 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.06m (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.06m market cap, or US$9.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). New Risk • Jan 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €8.57m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.57m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). New Risk • Nov 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€9.52m market cap, or US$11.1m). New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€11.5m market cap, or US$12.6m). Anuncio • May 27
Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024 Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024. Location: amphitheatre cuenot de l ensaia de l universite, de lorraine, 2 avenue de la foret de haye, vandoeuvre les nancy France New Risk • Apr 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Revenue is less than US$5m (€2.3m revenue, or US$2.5m). Market cap is less than US$100m (€11.5m market cap, or US$12.4m). Anuncio • Jan 10
Plant Advanced Technologies Announces the Official Launch of Its Latest Active Ingredient, Hydraqueen Exudactive®?1,3, and the Upcoming Cosmetic Range as Part of Its New Business Strategy Plant Advanced Technologies announced the official launch of its latest active ingredient, HydraQueen Exudactive®?1,3, and the upcoming cosmetic range as part of its new business strategy. The latest ingredient in the PAT Exudactive ®? collection, is extracted from meadowsweet root, a natural treasure full of molecules with proven biological activities for the skin. Its richness in secondary metabolites, multiplied by 82 due to the stimulation operation, makes it a real concentrate of benefits for the epidermis. This ingredient was carefully developed over several years by PAT teams and is the result of expertise in research engineering and optimization of plants grown and harvested in its aeroponic greenhouses. Innovative active ingredients that repair the skin barrier: a growing niche in Cosmetics This natural active ingredient is rich in molecules from the roots of the plant. Efficacy tests have demonstrated the benefits of HydraQueen Exudactive®®? for the skin: Restoration of the fragile balance of the skin's barrier function (+52% on D14); Helps defend the skin against pollution (TEER +17% on stressed mature skin), dehydration and environmental stress; Maintenance of internal hydration (+60% on day 14) and protection against external irritants; Helps repair and strengthen sensitive skin. Responsible innovation at the heart of PAT products: Responsible innovation is at the heart of Plant Advanced Technologies' approach. The Group has two unique research centers, one in Lorraine, the other on Reunion Island. These centers explore the products of tomorrow, while ensuring that nature and natural resources are preserved. With HydraQueen Exudactive®, PAT strives to preserve nature while offering the best of its activities thanks to production methods that respect the environment and natural resources: by the economy of cultivated areas - with 4 annual harvests and a life expectancy of at least 3 years in aeroponics By limiting water by recycling 100% of the culture water (closed cycle) By reasoned cultivation in biological control and biocontrol in a natural greenhouse - Zero pesticide By multiplying by 96 times the quantity of molecules collected VS in open fields. A sustainable sourcing and production chain to meet customers’ expectations HydraQueen Exudactive® ingredient is manufactured in France, with a fully controlled production chain traced from seed to active ingredient on the PAT site, thus guaranteeing: - quality: all of the company's activities are ISO9001-2015 certified, horticultural activities and aeroponic cultivation in Lorraine are labeled High Environmental Value (HVE) level 3. origin and transparency: PAT ingredients are RSPO MB certified, and all plants are sourced according to the Nagoya protocol in force, which aims to protect global biodiversity. “naturalness”: The ingredients are COSMOS and ISO16128 compatible – 100% natural origin. New Risk • Nov 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€7.72m market cap, or US$8.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€2.3m revenue, or US$2.5m). Major Estimate Revision • Oct 27
Consensus revenue estimates fall by 20% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €3.00m to €2.40m. Forecast loss of -€0.62, down from profit of €0.14 per share profit previously. Biotechs industry in France expected to see average net income growth of 21% next year. Consensus price target down from €24.60 to €15.70. Share price fell 30% to €6.75 over the past week. Breakeven Date Change • Oct 26
Forecast breakeven date pushed back to 2025 The analyst covering Plant Advanced Technologies previously expected the company to break even in 2023. New forecast suggests the company will make a profit of €1.20m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule. New Risk • Oct 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (€7.99m market cap, or US$8.46m). Minor Risk Revenue is less than US$5m (€2.3m revenue, or US$2.5m). Board Change • Nov 16
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 06
First half 2022 earnings released: €0.97 loss per share (vs €1.00 loss in 1H 2021) First half 2022 results: €0.97 loss per share (improved from €1.00 loss in 1H 2021). Revenue: €2.00m (up 7.2% from 1H 2021). Net loss: €1.05m (loss narrowed 3.0% from 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Breakeven Date Change • May 16
Forecast to breakeven in 2023 The analyst covering Plant Advanced Technologies expects the company to break even for the first time. New forecast suggests losses will reduce by 82% to 2022. The company is expected to make a profit of €800.0k in 2023. Average annual earnings growth of 136% is required to achieve expected profit on schedule. Board Change • Apr 27
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Price Target Changed • Nov 24
Price target decreased to €27.70 Down from €31.40, the current price target is provided by 1 analyst. New target price is 41% above last closing price of €19.65. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of €0.95 next year compared to a net loss per share of €0.61 last year. Anuncio • Mar 16
Plant Advanced Technologies SA to Report Fiscal Year 2020 Results on May 01, 2021 Plant Advanced Technologies SA announced that they will report fiscal year 2020 results on May 01, 2021 Is New 90 Day High Low • Jan 06
New 90-day high: €21.40 The company is up 12% from its price of €19.10 on 08 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: €20.80 The company is up 4.0% from its price of €20.00 on 22 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 32% over the same period. Is New 90 Day High Low • Nov 16
New 90-day low: €16.90 The company is down 15% from its price of €19.80 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Oct 13
New 90-day low: €18.30 The company is down 7.0% from its price of €19.60 on 15 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. Anuncio • Sep 22
Plant Advanced Technologies SA to Report First Half, 2020 Results on Oct 30, 2020 Plant Advanced Technologies SA announced that they will report first half, 2020 results on Oct 30, 2020 
